Researchmoz added Most up-to-date research on "Global Next-Generation Biologics Market 2016-2020" to its huge collection of research reports.
About Next-generation Biologics
According to the section 351 of the Public Health Service Act of the US FDA, a biological product is defined as a virus, therapeutic serum, antitoxin, vaccine, toxin, blood, blood component or derivative, analogous product or allergenic product, applicable to the treatment, prevention, or cure of a condition or disease of human beings. Biologic therapeutics include virus, toxins, allergenic products, therapeutic serums, antitoxin, blood components or derivatives, vaccines, blood, proteins (except any chemically synthesized polypeptide), or analogous products, or arsphenamine or derivative of arsphenamine intended for the treatment, prevention, or cure of a disease or condition. The differences between the small molecules and biologics includes the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics usually have a higher molecular weight and a complex molecular structure. They are usually derived from living organisms, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures and light.
Technavios analysts forecast the global next-generation biologics market to grow at a CAGR of 14.42% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
To Get Sample Copy of Report Visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=892950
Technavio's report, Global Next-generation Biologics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
F. Hofmann-La Roche
Novo Nordisk
Sanofi
Takeda Pharmaceuticals
Other prominent vendors
Aastrom Biosciences
AbbVie
AbGenomics
Acologix
ADC Therapeutics
Adocia
Agensys
AlloCure
AlloSource
ALMAC Group
Alphatec Spine
Ambrx
Amorcyte
Argos Therapeutics
Astellas Pharma
AstraZeneca
Athersys
Avita Medical
Baxter
Bayer HealthCare
Bellicum Pharmaceuticals
BioCardia
Biocon
Biodel
BIOGENOMICS
BioLife Solutions
Market driver
Advanced technological innovations
For a full, detailed list, view our report
Browse Detail Report With TOC @ https://www.researchmoz.us/global-next-generation-biologics-market-2016-2020-report.html/toc#table-of-content
Market challenge
Complexities in manufacturing of biologics
For a full, detailed list, view our report
Market trend
Development of gene and cell therapy-based products
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Table of Contents
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Five forces analysis
PART 06: Market segmentation by application
Global regenerative medicine market
Global next-generation antibodies market
Global next-generation insulin products market
Global next-generation recombinant coagulation factors market
PART 07: Geographical segmentation
Next-generation biologics market in Americas
Next-generation biologics market in EMEA
Next-generation biologics market in APAC
PART 08: Market drivers
Increase in demand for ADCs
Advanced technological innovations
Reimbursement support for next-generation biologics
Special regulatory drug designations for biologics
PART 09: Impact of drivers
PART 10: Market challenges
About Next-generation Biologics
According to the section 351 of the Public Health Service Act of the US FDA, a biological product is defined as a virus, therapeutic serum, antitoxin, vaccine, toxin, blood, blood component or derivative, analogous product or allergenic product, applicable to the treatment, prevention, or cure of a condition or disease of human beings. Biologic therapeutics include virus, toxins, allergenic products, therapeutic serums, antitoxin, blood components or derivatives, vaccines, blood, proteins (except any chemically synthesized polypeptide), or analogous products, or arsphenamine or derivative of arsphenamine intended for the treatment, prevention, or cure of a disease or condition. The differences between the small molecules and biologics includes the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics usually have a higher molecular weight and a complex molecular structure. They are usually derived from living organisms, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures and light.
Technavios analysts forecast the global next-generation biologics market to grow at a CAGR of 14.42% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
To Get Sample Copy of Report Visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=892950
Technavio's report, Global Next-generation Biologics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
F. Hofmann-La Roche
Novo Nordisk
Sanofi
Takeda Pharmaceuticals
Other prominent vendors
Aastrom Biosciences
AbbVie
AbGenomics
Acologix
ADC Therapeutics
Adocia
Agensys
AlloCure
AlloSource
ALMAC Group
Alphatec Spine
Ambrx
Amorcyte
Argos Therapeutics
Astellas Pharma
AstraZeneca
Athersys
Avita Medical
Baxter
Bayer HealthCare
Bellicum Pharmaceuticals
BioCardia
Biocon
Biodel
BIOGENOMICS
BioLife Solutions
Market driver
Advanced technological innovations
For a full, detailed list, view our report
Browse Detail Report With TOC @ https://www.researchmoz.us/global-next-generation-biologics-market-2016-2020-report.html/toc#table-of-content
Market challenge
Complexities in manufacturing of biologics
For a full, detailed list, view our report
Market trend
Development of gene and cell therapy-based products
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Table of Contents
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Five forces analysis
PART 06: Market segmentation by application
Global regenerative medicine market
Global next-generation antibodies market
Global next-generation insulin products market
Global next-generation recombinant coagulation factors market
PART 07: Geographical segmentation
Next-generation biologics market in Americas
Next-generation biologics market in EMEA
Next-generation biologics market in APAC
PART 08: Market drivers
Increase in demand for ADCs
Advanced technological innovations
Reimbursement support for next-generation biologics
Special regulatory drug designations for biologics
PART 09: Impact of drivers
PART 10: Market challenges
No comments:
Post a Comment